Thalassemia pathology for neet pg 2026 visual aod
thalassemia pathology types alpha beta molecular defects hemolysis ineffective erythropoiesis
thalassemia pathology diagram blood smear target cells ineffective erythropoiesis

| Feature | β-Thalassemia | α-Thalassemia |
|---|---|---|
| Gene affected | β-globin gene (chr 11) | α-globin gene (chr 16) |
| Mutation type | Predominantly point mutations | Predominantly deletions |
| Excess chain | α-chains accumulate | β, γ, Γ-chains accumulate |
| Tetramers formed | αā (Heinz bodies) | βā (HbH), γā (Hb Barts) |
| Oā affinity of tetramers | N/A (precipitate) | Very HIGH ā do not deliver Oā |
Severe Anemia
ā
Marrow Expansion (erythroid hyperplasia)
ā
āāāāāāāāāāāāāāāāāāāāāāāāāāāā¬āāāāāāāāāāāāāāāāāāāāāāāāāāā
ā Skeletal Changes ā Extramedullary ā
ā ⢠"Hair on end" ā Hematopoiesis ā
ā skull X-ray ā ⢠Hepatosplenomegaly ā
ā ⢠Crew-cut appearance ā ⢠Paraspinal masses ā
ā ⢠Frontal bossing ā ā
ā ⢠Rodent facies ā ā
āāāāāāāāāāāāāāāāāāāāāāāāāāāā“āāāāāāāāāāāāāāāāāāāāāāāāāāā
ā
Iron Overload (ā GI absorption + transfusions)
ā
Hemosiderosis ā Liver cirrhosis, Dilated CMP,
Diabetes, Hypogonadism
| Mediator | Role |
|---|---|
| ERFE (Erythroferrone) | ā in ineffective erythropoiesis ā ā Hepcidin |
| Hepcidin | ā ā ā Ferroportin activity ā ā GI iron absorption |
| TfR1 (Transferrin Receptor 1) | ā on erythroblasts ā increased iron uptake |
NEET PG Key Point: Ineffective erythropoiesis ā ā ERFE ā ā Hepcidin ā Iron overload. This is independent of transfusions.
| Genotype | Alleles deleted | Clinical Picture |
|---|---|---|
| Silent carrier | -α/αα (1 deleted) | Normal, asymptomatic |
| α-Thal trait | --/αα or -α/-α (2 deleted) | Mild microcytic anemia |
| HbH disease | --/-α (3 deleted) | Moderately severe hemolytic anemia, HbH (βā tetramers) |
| Hb Barts (Hydrops fetalis) | --/-- (4 deleted) | Incompatible with life, γā tetramers, severe tissue hypoxia |
HbH inclusions stain with brilliant cresyl blue ā "golf ball" cells
| Type | Genotype | Hb level | Transfusion |
|---|---|---|---|
| Thalassemia Minor (Trait) | β/β⺠or β/βⰠ| 9ā11 g/dL | Not required |
| Thalassemia Intermedia | βāŗ/β⺠| 6ā9 g/dL | Occasional |
| Thalassemia Major (Cooley's anemia) | βā°/βⰠ| <6 g/dL | Regular transfusions |
| Condition | HbA | HbA2 | HbF |
|---|---|---|---|
| Normal | 97% | 2.5% | <1% |
| β-Thal Minor | ā | ā (>3.5%) ā | ā slightly |
| β-Thal Major | Absent/āā | ā | āā (up to 90%) |
| α-Thal trait | ā | Normal/ā | Normal |
| HbH disease | ā | ā | Normal + HbH |
NEET PG Key: HbA2 >3.5% = hallmark of β-thalassemia trait. Used for carrier screening.
| System | Complication |
|---|---|
| Cardiac | Dilated cardiomyopathy (iron) ā #1 cause of death |
| Liver | Cirrhosis, hepatocellular carcinoma |
| Endocrine | Diabetes, hypogonadism, hypothyroidism, short stature |
| Bone | Osteoporosis, pathological fractures |
| Immune | Asplenia (post-splenectomy) ā encapsulated organisms |
| Treatment | Details |
|---|---|
| Regular blood transfusion | Target Hb >10 g/dL; monthly |
| Iron chelation | Desferrioxamine (IV/SC), Deferasirox (oral), Deferiprone (oral) |
| Splenectomy | Reduces transfusion requirement; risk of sepsis |
| Hydroxyurea | ā HbF production (β-thal intermedia) |
| Luspatercept | Anti-GDF11 ā ā ineffective erythropoiesis (newer drug) |
| HSCT (Bone Marrow Transplant) | Only curative option |
| Gene therapy | Betibeglogene (Zynteglo) ā approved for β-thalassemia |